PATENT CLAIM ANALYSIS

Application Number: 16251617
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "001110"]

Abstract:
Methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments are described, wherein R 1  is halo; R 2  is halo; and Q is CH or N.

Claim (Index 15):
The method according to any one of  claims 1 - 14 , wherein the compound of Formula I is administered to the patient in 25-125 mg dosages daily during the concurrent phase; TMZ is administered to the patient in 5-180 mg dosages daily to the patient during the concurrent phase;\n RT is administered to the patient during the concurrent phase using 1.8-2 Gy/fraction, daily for 5 days/week for a total dose of up to 60 Gy; the compound of Formula I is administered to the patient in 25-125 mg dosages daily during the maintenance phase; and TMZ is administered to the patient in 5-180 mg dosages for 5 consecutive days and repeated every 28 days until the cancer growth is slowed down.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 99.0
- Lexical Diversity: 1.33333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13145054', '14340871', '13249815', '11753514', '12393806']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8082197363612152
- 35 USC 102 Novelty (BERT): 0.5117379417892786
- Combined Prediction Score: 0.7785715569040216
- Mean Citation Score: 338.013512
- Max Citation Score: 351.83926
- Similarity Product: 167.11002557332998

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test